Treatment for ALK-mutated non-small-cell lung cancer: A new miracle in the research race

Clinical and Translational Oncology

Volumn 13, Issue 11, 2011, Pages 774-779

  De Castro Carpeno, Javier ^a   Perona, Rosario ^a   Belda Iniesta, Cristóbal ^a,b  

^a HOSPITAL UNIVERSITARIO LA PAZ IDIPAZ   (Spain)

^b CIOCC   (Spain)

Author keywords

ALK; ALK inhibitors; Crizotinib; NSCLC

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; HYBRID PROTEIN; K RAS PROTEIN; PEMETREXED; PLATINUM; PROTEIN EML4; PROTEIN KINASE INHIBITOR; PROTEIN TFG; TAE 684; UNCLASSIFIED DRUG;

ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RESEARCH; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL FEATURE; DIARRHEA; DOSE RESPONSE; DRUG BINDING; DRUG CYTOTOXICITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ENZYME ACTIVATION; ENZYME ASSAY; ENZYME INHIBITION; GASTROINTESTINAL SYMPTOM; GENE MUTATION; GENE REARRANGEMENT; GENE SEQUENCE; GENETIC VARIABILITY; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; NAUSEA; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; SIGNAL TRANSDUCTION; SOLID TUMOR; VISUAL DISORDER;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; MUTATION; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84856061380     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-011-0732-8     Document Type: Article

References (28)

1. Jemal A, Center MM, Desantis C, Ward EM (2010) Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 19:1893-1907
2. Morris SW, Kirstein MN, Valentine MB et al (1994) Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 263:1281-1284 (Pubitemid 24107549)
3. Shiota M, Fujimoto J, Semba T et al (1994) Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3. Oncogene 9:1567-1574 (Pubitemid 24163381)
4. Kutok JL, Aster JC (2002) Molecular biology of anaplastic lymphoma kinase-positive anaplastic large-cell lymphoma. J Clin Oncol 20:3691-3702 (Pubitemid 34983230)
5. Arber DA, Sun LH, Weiss LM (1996) Detection of the t(2;5)(p23;q35) chromosomal translocation 13 in large B-cell lymphomas other than anaplastic large cell lymphoma. Hum Pathol 27:590-594 (Pubitemid 26187284)
6. Pulford K, Morris SW, Turturro F (2004) Anaplastic lymphoma kinase proteins in growth control and cancer. J Cell Physiol 199:330-358 (Pubitemid 38580430)
7. Chiarle R, Voena C, Ambrogio C et al (2008) The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer 8:11-23
8. Soda M, Choi YL, Enomoto M et al (2007) Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448:561-566 (Pubitemid 47206930)
9. Pulford K, Lamant L, Espinos E et al (2004) The emerging normal and disease-related roles of anaplastic lymphoma kinase. Cell Mol Life Sci 61: 2939-2953 (Pubitemid 40104592)
10. George RE, Sanda T, Hanna M et al (2008) Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 455:975-978
11. Heidebrecht HJ, Buck F, Pollmann M et al (2000) Cloning and localization of C2orf2ropp120, a previously unknown WD repeat protein. Genomics 68:348-350
12. Radtke J, Rezaie SG, Kugler Ch et al (2010) Expression analysis of EML4 in normal lung tissue and non-small cell lung cancer (NSCLC) in the absence and presence of chemotherapeutics. Rom J Morphol Embryol 51:647-653
13. Takeuchi K, Choi YL, Soda M et al (2008) Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. Clin Cancer Res 14:6618-6624
14. Rikova K, Guo A, Zeng Q et al (2007) Global survey of phosphotyrosine signaling identifi es oncogenic kinases in lung cancer. Cell 131:1190-1203 (Pubitemid 350235027)
15. Takeuchi K, Choi YL, Togashi Y et al (2009) KIF5B-ALK, a novel fusion oncokinase identifi ed by an immunohistochemistry- based diagnostic system for ALK-positive lung cancer. Clin Cancer Res 15:3143-3149
16. Shi P, Lai R, Lin Q et al (2009) IGF-IR tyrosine kinase interacts with NPM-ALK oncogene to induce survival of T-cell ALK+ anaplastic large-cell lymphoma cells. Blood 114:360-370
17. Christensen JG, Zou HY, Arango ME et al (2007) Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther 6:3314-3322
18. Shaw AT, Yeap BY, Mino-Kenudson M et al (2009) Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 27:4247-4253
19. Kwak EL, Bang Y-J, Camidge DR et al (2010) Anaplastic lymphoma kinase inhibition in nonsmall- cell lung cancer. N Engl J Med 363:1693-1703
20. Rodig SJ, Mino-Kenudson M, Dacic S et al (2009) Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res 15:5216-5223
21. Shaw AT, Yeap BY, Solomon BJ et al (2011) Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: A retrospective analysis. Lancet Oncol 12:1004-1012
22. Perner S, Wagner PL, Demichelis F et al (2008) EML4-ALK fusion lung cancer: A rare acquired event. Neoplasia 10:298-302 (Pubitemid 351328588)
23. Choi YL, Takeuchi K, Soda M et al (2008) Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. Cancer Res 68:4971-4976
24. Choi YL, Soda M, Yamashita Y et al (2010) EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 363:1734-1739
25. Bossi RT, Saccardo MB, Ardini E et al (2010) Crystal structures of anaplastic lymphoma kinase in complex with ATP competitive inhibitors. Biochemistry 49:6813-6825
26. Lee CC, Jia Y, Li N et al (2010) Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain. Biochem J 430:425-437
27. Heuckmann JM, Hölzel M, Sos ML et al (2011) ALK mutations conferring differential resistance to structurally diverse ALK inhibitors. Clin Cancer Res [Epub ahead of print]
28. Sasaki T, Jänne PA (2011) New strategies for treatment of ALK rearranged non-small cell lung cancers. Clin Cancer Res [Epub ahead of print]